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Abstract
Purpose Nailfold videocapillaroscopy (NVC) identifies
the microvascular hallmarks of systemic sclerosis (SSc)
and vascular endothelial growth factor (VEGF) and may
play a pivotal role in the associated vasculopathy. The aim
of the present study was to compare NVC alterations with
clinical subsets, internal organ involvement, and serum
VEGF levels in a cohort of selected SSc cases.
Methods We studied 44 patients with SSc who were eval-
uated within 3 months from enrollment by NVC, skin score,
severity index, pulmonary function tests, carbon monoxide
diffusing capacity (DLCO), echocardiography, pulmonary
high-resolution computed tomography (HRCT), gastroe-
sophageal (GE) endoscopy ormanometry orX-ray, and serum
autoantibodies. Serum VEGF-A levels were determined by
ELISA in 72 SSc patients and 31 healthy controls.
Results Giant capillaries were inversely correlated with
age (p = 0.034, r = -0.34) and to the extent of reticular
pattern at HRCT (p = 0.04, r = -0.5). Avascular areas
were directly correlated with capillaroscopy skin ulcer risk
index (CSURI) (p = 0.006, r = ?0.4) and severity index
(p = 0.004, r = ?0.5). The mean capillary density was
directly correlated to the ulcer number (p = 0.02,
r = ?0.4) and to DLCO/alveolar volume (p = 0.02,
r = ?0.4) and inversely correlated with severity index
(p = 0.01, r = -0.4) and skin score (p = 0.02, r = -0.4).
Serum VEGF levels were higher in the SSc population vs
controls (p = 0.03) and inversely correlated with DLCO
(p = 0.01, r =-0.4) and directly with ground-glass and
reticular pattern at HRCT (p = 0.04, r = ?0.4 for both).
Conclusions Our data suggest the importance of NVC not
only for the diagnosis, but also for the global evaluation of
SSc patients. Of note, serum VEGF levels may act as a
biomarker of interstitial lung involvement.
Keywords Autoimmunity  Biomarkers  Personalized
medicine  Systemic sclerosis  Endothelium
Introduction
Systemic sclerosis (SSc) is an immune-mediated vascular
and fibrotic systemic disease [1], with striking female
predominance and with unknown pathogenesis involving
both genetics and environmental factors [2–5]. Microvas-
cular alterations underlying Raynaud’s phenomenon and
rearrangement of the capillary network characterize the
early phases of the disease. Nailfold videocapillaroscopy
(NVC) can easily identify SSc microvascular hallmarks as
giant capillaries and avascular areas, but also less specific
and frequent changes as ectasia, microhemorrhages, bushy
capillaries, and reduced capillary density. NVC is now
recognized as an indispensable tool for the early diagnosis
of SSc together with the presence of Raynaud’s phe-
nomenon and specific serum autoantibodies such as anti-
centromere and anti-topoisomerase I (anti-Scl70) [6]. The
NVC scleroderma pattern has been recently included in the
last SSc classification criteria [7], but the role of NVC
during the course of SSc is less defined. NVC alterations
can change with disease progression and severity, and
Cutolo et al. have reported three different NVC
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scleroderma patterns, i.e., early (presence of giant capil-
laries), active (prevalence of giant capillaries), and late
pattern (prevalence of avascular areas) [8], possibly mir-
roring the different phases of the disease. More recently,
Sebastiani et al., developed a score associated with ulcer
development called capillaroscopy skin ulcer risk index
(CSURI[2.94) [9], thus suggesting a role for NVC other
than the early diagnosis of SSc.
While the pathogenetic mechanisms in SSc remain
elusive, the vascular endothelial growth factor (VEGF) is
one of the main mediators of angiogenesis and vasculo-
genesis, being involved in SSc vasculopathy. Whether and
which changes in VEGF and its receptor levels are asso-
ciated with SSc and how they contribute to scleroderma
vasculopathy continue to be unclear [10–15].
The aim of this study is to investigate the correlations
between NVC alterations, Cutolo’s NVC patterns and
CSURI with the fine clinical SSc phenotype including
internal organ involvement, SSc severity score [16], and
serum VEGF levels in a cohort of well-defined SSc cases.
Patients and methods
Subjects
We enrolled 44 patients fulfilling the 2013 ACR/EULAR
criteria for SSc [7] without other overlapping rheumatic
diseases and for whom the following data were available:
NVC images of the right and left II–V fingers; all clinical,
immunologic, clinimetric, and instrumental evaluations
(Table 1); and one serum sample for each SSc patient. All
SSc cases were evaluated between 2001 and 2014, but serum
samples, clinical, and instrumental data analyzed in the study
were obtained within 3 months from NVC. The character-
istics of the study population are summarized in Table 1.
Serum samples of 31 female healthy subjects (median age
65 years, range 3–80 years) and additional 32 women with
SSc (median age 67 years, range 40–78; median disease
duration 8 years, range 1–17 years; diffuse SSc 10; ACA
(?) 17 cases; anti-Scl70 (?) 8 cases) were also obtained and
used as controls. All subjects enrolled signed a written
informed consent for serum samples and data analysis after
approval from the local ethical committee.
NVC analysis
Two independent readers (MDS and CC), blinded to
patient information, analyzed and recorded the mean cap-
illary density per finger and the total numbers of giant
capillaries, neoangiogenesis, and avascular areas on four
consecutive NVC fields extending over 1 mm, in the
middle of the nailfold of the right and left second, third,
fourth, and fifth fingers; early, active, and late scleroderma
patterns, as described by Cutolo et al. [8], and CSURI as
described by Sebastiani et al. [9] were assessed.
Clinical and imaging assessment
Age, disease duration (from the first non-Raynaud symp-
tom), cutaneous subset, modified Rodnan skin score
(mRSS), digital ulcers (current), SSc severity index [16],
and treatments received were analyzed. All patients
underwent echocardiography for pulmonary hypertension
screening with systolic pulmonary artery pressure (sPAP)
assessment (3 patients had PAPs [45 mmHg related to
interstitial lung disease); pulmonary function tests for
forced vital capacity (FVC) and carbon monoxide diffusing
capacity (DLCO) and DLCO/alveolar volume (DLCO/AV)
assessment; high-resolution computed tomography of the
lung (HRCT) with the assessment of ground-glass reticular
pattern and honeycombing extent as described elsewhere
[17–19]. Gastro-esophageal (GE) involvement was inves-
tigated during history and assessed in symptomatic patients
with esophageal manometry or X-ray or endoscopy.
Table 1 Characteristics of the SSc cohort (n = 44)
SSc (n = 44)
F (%) vs M (%) 42 (95.4 %) vs 2 (4.6 %)
Median age, yy(range) 66 (34–80)
Median disease duration, yy (range) 9 (1–16)
D (%) vs L (%) 10 (22.7 %) vs 34 (77.3 %)
anti-Scl70 (?) (%) 12 (27.3 %)
ACA (?) (%) 22 (50 %)
Others Abs (%)a 10 (22.7 %)
Iloprost (%) 25 (56.8 %)
Bosentan (%) 7 (15.9 %)
Ulcers (%) 15 (34.1 %)
Early NVC pattern (%) 6 (13.6 %)
Active NVC pattern (%) 20 (45.4 %)
Late NVC pattern (%) 18 (40.9 %)
GE disease (%) 36 (81.8 %)
sPAP[45 mmHg (%) 3 (6.8 %)
DLCO\50 % (%)
DLCO/AV\50 % (%)
7 (15.9 %)
1 (2.3 %)
FVC\80 % (%) 8 (18.2 %)
Honeycombing lung (%) 4 (9.1 %)
Rodnan skin score[14 (%) 9 (20.4 %)
ACA anti-centromere, anti-Scl70 anti-topoisomerase, AV alveolar
volume, D diffuse, DLCO carbon monoxide diffusing capacity, F fe-
male, FVC forced vital capacity, GE gastro-esophageal, L limited,
M male, NVC nailfold videocapillaroscopy, sPAP systolic pulmonary
artery pressure on echocardiography, SSc systemic sclerosis, vs versus
a 1/10 anti-Ku, 2/10 anti-RNApol III, 1/10 anti-Th/To
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Laboratory tests
Serum was obtained from the peripheral blood of the 44 SSc
patients included in the study, 32 unselected SSc patients, and
31 sex- and age-matched healthy controls. Laboratory tests for
SSc cases included complete blood cell count, C-reactive
protein (CRP) level, serum creatinine concentration, urine
analysis, complementC3 andC4,ACA (immunofluorescence
on Hep2 cells), anti-Scl70 (ELISA), protein immunoprecipi-
tation (IP) of K562 cell extract radiolabeled with 35S-me-
thionine and by RNA-IP through silver staining; specificities
of autoantibodies were determined using specific reference
sera [20, 21] for serum antibody assessment.
VEGF-A was measured by quantitative sandwich
enzyme-linked immunosorbent assay (ELISA) (Quantikine
kits; R&D). Concentrations were calculated using a stan-
dard curve generated with specific standards provided by
the manufacturer.
Statistical analysis
All data are presented as median and range for continuous
variables. The two-sample Mann–Whitney’s test and con-
tingency tables were used as appropriate. The Spearman’s
test was used for correlations. P values\0.05 were con-
sidered to be significant.
Results
Our analysis was performed on 44 SSc cases, 32 unselected
SSc patients, and 31 sex- and age-matched healthy con-
trols. The number of giant capillaries was inversely cor-
related with age (p = 0.034, r = -0.34; Fig. 1a) and to the
extent of reticular pattern on HRCT (p = 0.04, r = -0.5,
Fig. 1b). The number of giant capillaries was higher in
patients without serum anti-Scl70 or ACA and in those
with skin score[14 (p = ns; Table 2). As expected, the
number of giant capillaries was significantly higher in
patients with active NVC pattern (p\ 0.0001; Table 2).
The degree of neoangiogenesis was higher in SSc patients
with GE involvement, honeycombing, DLCO\50 %, sPAP
[45 mmHg, higher VEGF levels (Table 2), and in SSc
patients treated with bosentan (p = 0.016; Table 2).
The number of avascular areas was directly correlated to
severity index (p = 0.004, r = ?0.5; Fig. 2a) and inversely
to DLCO/AV (p = 0.02, r = -0.4; Fig. 2b). Moreover, the
number of avascular areas was higher in SSc patients with
anti-Scl70 orACA (p = ns; Table 2) and in those with higher
sPAP (p = 0.03; Table 2) or needing iloprost (p = 0.04;
Table 2) or bosentan (p = ns; Table 2) for digital ulcers. As
expected, the number of avascular areas was significantly
higher in patients with late NVC pattern (p\ 0.0001;
Table 2) and CSURI[2.94 (p = 0.01; Table 2).
The mean capillary density was directly correlated with
the number of digital ulcers (p = 0.02, r = ?0.4) and to
DLCO/AV (p = 0.02, r = ?0.4), and inversely with the
severity index (p = 0.01, r = -0.4; Fig. 3a) and skin
score (p = 0.02, r = -0.4; Fig. 3b). Moreover, the mean
capillary density was lower in patients with anti-Scl70, skin
score[14, (p = ns; Table 2), and, as expected, in patients
with late NVC pattern (p = 0.0007; Table 2) and CSURI
\2.94 (p = 0.047; Table 2). The highest mean capillary
density was found in patients with early NVC pattern
(p = 0.005; Table 2).
Cutolo’s NVC late pattern was significantly more
prevalent in SSc with higher sPAP (p = 0.025; Table 3)
and honeycombing (p = 0.037; Table 3), in patients
receiving iloprost (p = 0.039; Table 3) or bosentan
(p = 0.017; Table 3) for digital ulcers, and in those with
the lowest VEGF levels (p = 0.02; Table 3). Moreover,
the late pattern was significantly less frequent in patients
with CSURI\2.94 (p = 0.02; Table 3).
CSURI directly correlated wih the number of avascular
areas (p = 0.006, r = ?0.4) and was higher in patients
with late NVC pattern (p = 0.02; Table 3).
Fig. 1 Giant capillaries inversely correlated with age and reticular pattern on high-resolution computed tomography
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Serum VEGF-A was higher in SSc vs healthy controls
(median 0.5, range 0.02–3.05 vs median 0.4, range 0.2–0.5,
respectively; p = 0.03). Among SSc cases, VEGF-A was
inversely correlated with DLCO (p = 0.01, r = -0.4;
Fig. 4b), and directly with ground-glass and reticular pat-
tern extent on HRCT (p = 0.04, r = ?0.4 for both;
Fig. 4b). Moreover, VEGF-A levels were lower in the
serum of SSc patients with evidence of interstitial lung
disease (median 0.39, range 0.1–3.05 vs median 0.48, range
0.14–1.70, respectively; p = 0.44).
Discussion
The hallmarks of the NVC scleroderma pattern include
giant capillaries and avascular areas, albeit poorly specific
for SSc, as they are also observed in other connective tissue
diseases characterized by Raynaud’s phenomenon or
interstitial lung disease such as dermatomyositis and mixed
connective tissue disease [22]. Nevertheless, almost all
scleroderma patients had one or both of those alterations,
while the association of scleroderma pattern to other con-
nective tissue diseases is not quite clear, especially for rare
diseases as anti-synthetase syndrome [23, 24]. The present
study was aimed at a clear definition of the NVC patterns
and fine phenotyping in well-defined SSc clinical subtypes
in association with serum VEGF-A levels. Our data
cumulatively support the finding that NVC may be helpful
not only for the diagnosis, but also for the global and
longitudinal evaluation of patients with SSc. Further,
serum VEGF-A levels may represent a biomarker to pre-
dict interstitial lung involvement in SSc.
In our cohort, the crude prevalence of giant capillaries
and avascular areas appears to be related to the severity of
the disease as indicated by the correlations with interstitial
lung disease, sPAP, higher skin score, or SSc severity
index. When confirmed in larger cohorts, these data may
suggest a helpful role of this simple counting score as
marker of internal organ involvement. Moreover, it would
be interesting to test it in cases of SSc sine scleroderma or
in other connective tissue diseases with NVC scleroderma
pattern and risk of interstitial lung disease or pulmonary
arterial hypertension. Another interesting point is to
explore NVC in SSc patients with rare autoantibodies,
since in our cohort SSc patients with rare autoantibodies
seem to have more giant capillaries compared to avascular
Fig. 2 Avascular areas directly correlated with severity index and inversely with DLCO/AV
Fig. 3 Mean capillary density correlated inversely with severity index e with skin score
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areas; however, lower SSc disease duration was found in
this small group of patients.
Assessing Cutolo’s pattern is time sparing, but does not
allow a quantitative analysis of microvasculopathy. On the
other hand, CSURI is time-consuming and provides limited
information. Based on our results, themost helpful and simple
data to collect is the mean capillary density. In fact, this
parameter not only correlates with an important pulmonary
function index (DLCO/AV), but alsowith SSc skin score, SSc
severity index, and with the presence of digital skin ulcers.
The scleroderma NVC pattern and, particularly, the
presence of giant capillaries usually predate skin fibrosis as
observed in patients reporting with Raynaud’s phe-
nomenon. In fact, vasculopathy is thought to precede and
possibly cause fibrosis in SSc. The exact mechanism
leading to giant capillary development and then to avas-
cular areas appearance is not known. It has been reported
that the chronic overexpression of VEGF can lead to
enlarged capillary development [25] and that higher levels
of VEGF characterize the early phase of SSc when giant
capillaries are often the first manifestation of SSc [26].
However, in our study, serum VEGF-A levels did not show
any association with NVC alterations. A large study
enrolling early SSc is necessary to explore this point,
especially when aiming at defining biomarkers for early
diagnosis and treatment of SSc [27].
Interstitial lung disease is frequent in SSc patients and in
a not well-defined subset of subjects is fatally progressive,
being the leading cause of death [28]. We have previously
reported lower bronchoalveolar lavage fluid VEGF-A
levels in SSc patients with lung involvement, particularly
in those with alveolitis on bronchoalveolar lavage fluid
analysis and ground-glass on lung HRCT [29]. In healthy
adults, an excess of VEGF in the lung compared to other
tissues contributes to normal lung tissue homeostasis and
endothelial tropism [30]. Nevertheless, in SSc an imbal-
ance between compartments seems to characterize patients
with interstitial lung disease, but the pathogenic
significance of these data remains to be elucidated. Several
reports demonstrated lower VEGF levels in different
interstitial lung diseases as lung fibrosis and sarcoidosis
[31], but bronchoalveolar lavage fluid analysis is uncom-
fortable for patients and is not recommended as a routine
examination in lung diseases, but in lower airway infection
diagnosis [32]. When confirmed in larger SSc cohorts,
serum VEGF levels together with pulmonary function tests
could be a useful biomarker of interstitial lung disease,
maybe better identifying patients needing lung HRCT;
moreover, it would be interesting to explore if serum
VEGF level changes during the course of SSc, i.e., mir-
roring lung function decline or predicting progression of
SSc interstitial lung disease on HRCT.
Conclusions
Our data support the importance of NVC not only for the
early diagnosis of SSc, but also in the evaluation and
possibly prediction of the severity and organ involvement
of SSc. We further suggest that prospective studies, ideally
multicentric, may confirm the role of serum VEGF levels
as putative biomarkers of SSc pulmonary interstitial
involvement.
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